Ulcerative Colitis Clinical Case Review

Michael Dolinger, MD, an assistant professor of pediatric gastroenterology at the Icahn School of Medicine and Mount Sinai Kravis Children's Hospital, presents information on the available treatment options:

Editor’s note: The following is an automatically generated transcript of the above video.

“And so, when we talk to her, we're talking right then in the clinic, talking about treatment options. We're not waiting until the evening when stool tests come back, when lab tests are going to come back the next day. And we're not waiting two weeks for a calprotectin. And we're not scheduling a flexible sigmoidoscopy or colonoscopy. We're making a decision to escalate therapy from mesalamine to biologic therapy right here.

And here are the treatment options we talk through. Infliximab [Remicade; Janssen], adalimumab [Humira; AbbVie], vedolizumab [Entyvio; Takeda], Ustekinumab [Stelara; Janssen], and an S1P inhibitor, ozanimod [Zeposia; Bristol Myers Squibb]. All have different benefits, speed, safety, convenience. And we talked to her in the context of going back to school in the fall and what she may most prefer. Does she want to talk about IV infusions? Does she want to talk about self-injectable medicine? Turns out she has a fear of injecting herself, doesn't want to go to the nurse at the school.”